This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lozniewski, A.
Right arrow Articles by Mory, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lozniewski, A.
Right arrow Articles by Mory, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2001, p. 2933-2935, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2933-2935.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Antimicrobial Susceptibilities of Clinical Desulfovibrio Isolates

A. Lozniewski,1 R. Labia,2 X. Haristoy,1 and F. Mory1,*

Laboratoire de Bactériologie, Hôpital Central, CHU, 54035 Nancy Cedex,1 and CNRS-UBO-MNHN, Unité FRE 2125, 29000 Quimper,2 France

Received 27 November 2000/Returned for modification 3 June 2001/Accepted 19 July 2001

The antimicrobial susceptibilities of 16 clinical isolates of Desulfovibrio spp. were determined. All or most isolates were susceptible to imipenem (MIC90 [MIC at which 90% of the isolates tested were inhibited], 0.5 µg/ml), metronidazole (MIC90, 0.25 µg/ml), clindamycin (MIC90, 4 µg/ml), and chloramphenicol (MIC90, 16 µg/ml) but were resistant or intermediate to penicillin G (MIC90, 64 µg/ml), piperacillin (MIC90, 256 µg/ml), piperacillin-tazobactam (MIC90, 256 µg/ml), cefoxitin (MIC90, >256 µg/ml), and cefotetan (MIC90, 64 µg/ml). Among isolates with decreased susceptibility to beta -lactams (n = 15), only six were beta -lactamase positive and susceptible to amoxicillin-clavulanate and ticarcillin-clavulanate.

* Corresponding author. Mailing address: Laboratoire de Bactériologie, Hôpital Central, 29 Avenue du Maréchal de Lattre de Tassigny, 54035 Nancy Cedex, France. Phone: (33) 3.83.85.14.34. Fax: (33) 3.83.85.26.73. E-mail: f.mory{at}chu-nancy.fr.

Antimicrobial Agents and Chemotherapy, October 2001, p. 2933-2935, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2933-2935.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Warren, Y. A., Citron, D. M., Merriam, C. V., Goldstein, E. J. C. (2005). Biochemical Differentiation and Comparison of Desulfovibrio Species and Other Phenotypically Similar Genera. J. Clin. Microbiol. 43: 4041-4045 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Peraino, V. A., Cross, S. A. (2003). Desulfovibrio desulfuricans Bacteremia and Review of Human Desulfovibrio Infections. J. Clin. Microbiol. 41: 2752-2754 [Abstract] [Full Text]  
  • Morin, A.-S., Poirel, L., Mory, F., Labia, R., Nordmann, P. (2002). Biochemical-Genetic Analysis and Distribution of DES-1, an Ambler Class A Extended-Spectrum {beta}-Lactamase from Desulfovibrio desulfuricans. Antimicrob. Agents Chemother. 46: 3215-3222 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»